Hints and tips:
Related Special Reports
...The company is aiming to develop a wide range of drugs and use its manufacturing scale to stay ahead of pharmaceutical rivals seeking to profit from consumer “hype” for weight loss products, he added....
...Zealand’s products in development will have to compete with the popular Wegovy and Zepbound drugs already on the market and made by Novo Nordisk and Eli Lilly respectively, which suppress appetite....
...If the trials approved by the Medicines and Healthcare products Regulatory Agency are successful, the drug will be the first cancer therapy developed on the island of Ireland....
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...It already made its diagnostics products in the country but had “limited manufacturing for pharma”, he added....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...The UK-based pharmaceutical group reported revenue of $12.7bn for the first quarter of 2024, an increase of 19 per cent, well ahead of consensus estimates of $11.9bn....
...While money from Covid vaccine sales is a key driver of the dispute, the patent battle could prove influential for the development of future mRNA-based products....
...AstraZeneca is a specialist in cancer treatments, making $17bn and 37 per cent of sales from oncology products in 2023....
...Meanwhile, a trial is looking at whether metformin, commonly prescribed for type 2 diabetes, might delay the development of other chronic diseases....
...“It will encourage them to make sure the medicines are available here and it’s a route for people to get tested with the new medicines in development.”...
...Daiichi Sankyo, which developed the drug with AstraZeneca and leads on marketing of the product in the UK, said it was “extremely disappointed by the decision”....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...Pharmaceutical companies must replenish their drugs pipeline before exclusivity rights on top-selling products expire....
...Jeff Emmick, Eli Lilly’s senior vice-president of product development, said that while as many as 80mn US adults may suffer from obstructive sleep apnoea, about a quarter of whom face more serious symptoms...
...Pharmaceutical companies also have a key role to play in providing affordable access to these essential products. The global industry’s response to date has been inadequate and fragmented....
...make up the backbone of pharmaceutical care....
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
...The global contract development and manufacturing market, which supports pharma companies in making products and running clinical trials, is projected to grow from $72bn to $90bn over the next two years,...
...But she said believed new entrants would be able to break into the market “if the product is sufficiently differentiated”....
...Lex has been watching the development of this market closely....
...But Eli Lilly declined to say how much of the product would be available in Britain, or which pharmacies will stock the product. Patients in Northern Ireland will not have access to the pen....
...Zealand expects 10 per cent royalties from any eventual sales of the product....
...“The issue affects anyone developing antifungal drugs because regulatory requirements make the development time for human medicines much longer than for agricultural chemicals,” said Birch....
...Drugs made by Japan’s Eisai and Eli Lilly of the US have shown promise when used early in an individual’s development of the disease....
International Edition